SANES

10.222

+0.31%↑

BBVA

18.585

+0.57%↑

CABK

10.705

+0.52%↑

INGA

25.41

+1.01%↑

NDA.FI

15.38

-0.52%↓

SANES

10.222

+0.31%↑

BBVA

18.585

+0.57%↑

CABK

10.705

+0.52%↑

INGA

25.41

+1.01%↑

NDA.FI

15.38

-0.52%↓

SANES

10.222

+0.31%↑

BBVA

18.585

+0.57%↑

CABK

10.705

+0.52%↑

INGA

25.41

+1.01%↑

NDA.FI

15.38

-0.52%↓

SANES

10.222

+0.31%↑

BBVA

18.585

+0.57%↑

CABK

10.705

+0.52%↑

INGA

25.41

+1.01%↑

NDA.FI

15.38

-0.52%↓

SANES

10.222

+0.31%↑

BBVA

18.585

+0.57%↑

CABK

10.705

+0.52%↑

INGA

25.41

+1.01%↑

NDA.FI

15.38

-0.52%↓

Home・Listă Acțiuni・Ipsen SA.

Ipsen SA.

Deschisă

SectorFinanțe

164.4 -0.45

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

163.8

Maxim

166.3

Indicatori cheie
By Trading Economics
Venit	-225M 110M
Vânzări	36M 1.9B
P/E Medie Sector	31.238 57.018
Randament dividend	0.84
Marjă de profit	5.899
Angajați	5,535
EBITDA	-171M 466M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-12.46% downside

Dividende
By Dow Jones
Randament dividend Medie Sector	0.84% 4.62%
Următoarele câștiguri	30 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	2.4B 14B
Deschiderea anterioară	164.85
Închiderea anterioară	164.4

Sentimentul știrilor

By Acuity

32%

68%

101 / 439 Clasament în Finance

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

99.85 / 104 Suport & Rezistență

Ipsen SA. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 mai 2026, 22:50 UTC

Câștiguri

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mai 2026, 22:49 UTC

Câștiguri

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mai 2026, 22:32 UTC

Câștiguri

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mai 2026, 22:57 UTC

Market Talk

Câștiguri

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mai 2026, 22:26 UTC

Câștiguri

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mai 2026, 22:25 UTC

Câștiguri

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mai 2026, 22:25 UTC

Câștiguri

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mai 2026, 22:24 UTC

Câștiguri

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mai 2026, 22:23 UTC

Câștiguri

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mai 2026, 22:23 UTC

Câștiguri

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mai 2026, 22:19 UTC

Câștiguri

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mai 2026, 22:14 UTC

Câștiguri

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mai 2026, 22:14 UTC

Câștiguri

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mai 2026, 22:13 UTC

Câștiguri

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mai 2026, 22:12 UTC

Câștiguri

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mai 2026, 22:12 UTC

Câștiguri

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mai 2026, 22:11 UTC

Câștiguri

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mai 2026, 22:11 UTC

Câștiguri

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mai 2026, 22:10 UTC

Câștiguri

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mai 2026, 22:09 UTC

Câștiguri

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mai 2026, 22:09 UTC

Câștiguri

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mai 2026, 22:08 UTC

Câștiguri

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mai 2026, 22:07 UTC

Câștiguri

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mai 2026, 22:06 UTC

Câștiguri

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mai 2026, 22:06 UTC

Câștiguri

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mai 2026, 22:05 UTC

Câștiguri

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mai 2026, 22:04 UTC

Câștiguri

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mai 2026, 22:04 UTC

Câștiguri

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mai 2026, 22:04 UTC

Câștiguri

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparație

Modificare preț

Ipsen SA. Așteptări

Obiectiv de preț

By TipRanks

-12.46% jos

Prognoză pe 12 luni

Medie 144 EUR -12.46%

Maxim 170 EUR

Minim 130 EUR

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIpsen SA. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

4 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 4 analiști care au acordat evaluări ale acțiunilor Ipsen SA. - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

99.85 / 104Suport & Rezistență

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

101 / 439 Clasament în Finanțe

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.